Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania.

Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0022-1899 (Print) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press

Polymerase Chain Reaction*; Artemisinins/*therapeutic use ; DNA, Protozoan/*blood ; Ethanolamines/*therapeutic use ; Fluorenes/*therapeutic use ; Malaria, Falciparum/*drug therapy ; Malaria, Falciparum/*parasitology ; Plasmodium falciparum/*isolation & purification ; Pyrimethamine/*therapeutic use ; Sulfadoxine/*therapeutic use; Animals ; Antigens, Protozoan/genetics ; Antimalarials/therapeutic use ; Artemether, Lumefantrine Drug Combination ; DNA, Protozoan/genetics ; Drug Combinations ; Genotype ; Humans ; Merozoite Surface Protein 1/genetics ; Plasmodium falciparum/classification ; Plasmodium falciparum/genetics ; Protozoan Proteins/genetics ; Recurrence ; Tanzania

We assessed the influence that consecutive-day blood sampling, compared with single-day blood sampling, had on polymerase chain reaction (PCR)-adjusted parasitological cure after stepwise genotyping of merozoite surface proteins 2 (msp2) and 1 (msp1) in 106 children in Tanzania who had uncomplicated falciparum malaria treated with either sulfadoxine-pyrimethamine or artemether-lumefantrine; 78 of these children developed recurrent parasitemia during the 42-day follow-up period. Initial msp2 genotyping identified 27 and 33 recrudescences by use of single- and consecutive-day sampling, respectively; in subsequent msp1 genotyping, 17 and 21 of these episodes, respectively, were still classified as recrudescences; these results indicate a similar sensitivity of the standard single-day PCR protocol--that is, 82% (27/33) and 81% (17/21), in both genotyping steps. Interpretation of PCR-adjusted results will significantly depend on methodology.

0 (Antigens, Protozoan)
0 (Antimalarials)
0 (Artemether, Lumefantrine Drug Combination)
0 (Artemisinins)
0 (DNA, Protozoan)
0 (Drug Combinations)
0 (Ethanolamines)
0 (Fluorenes)
0 (Merozoite Surface Protein 1)
0 (Protozoan Proteins)
0 (merozoite surface protein 2, Plasmodium)
37338-39-9 (fanasil, pyrimethamine drug combination)
88463U4SM5 (Sulfadoxine)
Z3614QOX8W (Pyrimethamine)

Date Created: 20070119 Date Completed: 20070319 Latest Revision: 20181201

20240829

10.1086/510910

17230421